Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

BACKGROUND: Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options. METHODS: In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced urothelial cancer that recurred or...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Mai, Y., Poehlein, C.H., Perini, R.F., Bajorin, D.F.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5635424/
https://ncbi.nlm.nih.gov/pubmed/28212060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1613683
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares